Please use this identifier to cite or link to this item: https://covid-19.conacyt.mx/jspui/handle/1000/4532
Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
Sangeun Jeon.
Meehyun Ko.
Jihye Lee.
Inhee Choi.
Soo Young Byun.
Soonju Park.
David Shum.
Seungtaek Kim.
Acceso Abierto
Atribución-NoComercial-SinDerivadas
10.1101/2020.03.20.999730
COVID-19 is an emerging infectious disease and was recently declared as a pandemic by WHO. Currently, there is no vaccine or therapeutic available for this disease. Drug repositioning represents the only feasible option to address this global challenge and a panel of 48 FDA-approved drugs that have been pre-selected by an assay of SARS-CoV was screened to identify potential antiviral drug candidates against SARS-CoV-2 infection. We found a total of 24 drugs which exhibited antiviral efficacy (0.1 M < IC50 < 10 M) against SARS-CoV-2. In particular, two FDA-approved drugs - niclosamide and ciclesonide - were notable in some respects. These drugs will be tested in an appropriate animal model for their antiviral activities. In near future, these already FDA-approved drugs could be further developed following clinical trials in order to provide additional therapeutic options for patients with COVID-19.
www.biorxiv.org
2020
Artículo
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v3.full.pdf
Inglés
VIRUS RESPIRATORIOS
Appears in Collections:Artículos científicos

Upload archives


File SizeFormat 
1106735.pdf1.28 MBAdobe PDFView/Open